Screener / SEC EDGAR /CIK 0000070318 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Hospitals

Tenet Healthcare Corp THC

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What THC's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Tenet Reports Strong Third Quarter 2026 Results;

Open on SEC

Net income available to common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third quarter 2025

increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third quarter 2025

increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026 Adjusted EBITDA margin was 24.1%

Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased 9.1% over third quarter 2025

FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05 billion to $5.20 billion, a $195 million increase at the midpoint of the range; FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of $2.825 billion to $3.125 billion, a $100 million increase

Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026.

"Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow." Page 1 Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:

• Net income available to the Company’s common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or $3.86 per diluted share, in third quarter 2025.

• The Company had previously entered into certain agreements with CommonSpirit Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the parties agreed, in part, to the early conclusion and transition of our revenue cycle management services by December 31, 2026, (collectively, the "RCM Agreements").

• The transition of certain revenue cycle management services under the RCM Agreements occurred during the third quarter of 2026 and will be substantially complete by October 30, 2026. As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million. These are timing-related adjustments and as such, do not impact total or full year 2026 expectations for revenue from contract termination or net operating revenues associated with the RCM Agreements.

• In addition, we recognized a benefit of approximately $50 million during the three months ended September 30, 2026 due to various transition activities, including efficiencies from the revised timeline described above. This, combined with the $97 million timing-related adjustment to net operating revenue mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147 million in the third quarter of 2026.

• Adjusted EBITDA 1 was $1.355 billion in third quarter 2026 compared to $1.099 billion in third quarter 2025, reflecting strong same facility revenue growth and disciplined expense management partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the $147 million favorable net impact described above. Page 2 Balance Sheet and Cash Flows

• Net cash flows provided by operating activities for the nine months ended September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months ended September 30, 2025.

• The Company generated adjusted free cash flow 1 of $2.524 billion for the nine months ended September 30, 2026 versus $2.247 billion for the nine months ended September 30, 2025.

• In the three months ended September 30, 2026, the Company repurchased 970,000 shares of common stock for $255 million. In the nine months ended September 30, 2026, the Company repurchased 7.99 million shares of common stock for $1.615 billion.

• In September 2026, the Company completed a private placement of $2.0 billion in aggregate principal amount of newly issued 6.250% senior notes maturing in 2034. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion aggregate principal amount then outstanding of its 5.125% senior secured first lien notes due in 2027 and the partial redemption of $500 million outstanding of its 6.125% senior notes due in 2028.

• The Company’s ratio of net debt to Adjusted EBITDA 1 was 2.11x at September 30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025. Page 3

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2026, USPI had interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical hospitals (seven consolidated) in 37 states.

• Third quarter 2026 net operating revenues increased 7.5% compared to third quarter 2025 driven by strong growth in consolidated same-facility net patient service revenues, acquisitions of facilities, and increased service lines.

• Surgical business same-facility system-wide net patient service revenues increased 4.5% in third quarter 2026 compared to third quarter 2025, with cases down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was driven by higher acuity and favorable service mix.

• Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter 2025, due to strong growth in same-facility net patient service revenues, disciplined expense management, and contributions from acquisitions. Page 4 Hospital Operations and Services (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro- hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.

• Third quarter 2026 net operating revenues increased 6.1% from third quarter 2025 driven by an increase in adjusted admissions as well as continued pricing strength, partially offset by unfavorable payer mix due to lower exchange admissions. In addition, third quarter 2026 net operating revenues include a timing-related benefit of $97 million associated with the RCM Agreements as described on page 2.

• Same-hospital net patient service revenue per adjusted admission increased 0.2% year-over-year for third quarter 2026 primarily due to strength in commercial employer net patient revenues offset by unfavorable payer mix related to lower exchange admissions.

• Adjusted EBITDA in third quarter 2026 was $818 million compared to $607 million in third quarter 2025, reflecting strong growth in same-hospital revenue and disciplined expense management, partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the net favorable impact of $147 million from transition activities described on page 2.

• In the third quarter of 2026, the Hospital segment recognized a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. Third quarter 2025 results included a $38 million favorable pre-tax impact for additional Medicaid supplemental revenues related to prior years. Page 5

Tenet’s Outlook for full year 2026 (consolidated and by segment) follows. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.

CONSOLIDATED($ in millions, except per share FY 2026 Outlook amounts) Net operating revenues7 $22,050 to $22,450 Net income available to Tenet common shareholders $2,973 to $3,078 Adjusted EBITDA $5,050 to $5,200 Adjusted EBITDA margin 22.9% to 23.2% Diluted income per common share $35.82 to $37.08 Adjusted net income $1,830 to $1,910 Adjusted diluted earnings per share $22.05 to $23.01 Equity in earnings of unconsolidated affiliates $265 to $275 Depreciation and amortization $865 to $915 Interest expense $815 to $825 Income tax expense5 $1,135 to $1,170 Net income available to NCI $910 to $960 Weighted average diluted common shares ~83 million Net cash provided by operating activities $3,885 to $4,315 Adjusted net cash provided by operating activities $3,525 to $3,925 Capital expenditures $700 to $800 Free cash flow $3,185 to $3,515 Adjusted free cash flow $2,825 to $3,125 NCI cash distributions $900 to $970

Ambulatory Segment($ in millions) FY 2026 Outlook Net operating revenues $5,530 to $5,670 Adjusted EBITDA $2,160 to $2,220 NCI $865 to $895 Adjusted EBITDA less NCI $1,295 to $1,325 Changes versus prior year6: Same-facility system-wide revenues Up 3.0% to 6.0%

Hospital Segment($ in millions) FY 2026 Outlook Net operating revenues7 $16,520 to $16,780 Adjusted EBITDA $2,890 to $2,980 NCI $45 to $65 Changes versus prior year6: Inpatient admissions Up 1.0% to 2.0% Adjusted admissions Up 1.0% to 2.0%

Tenet management will discuss the Company’s third quarter 2026 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2026. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2026. Page 7

This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission .

1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2026 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non- GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.

2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.

3. For 2026, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2025 through September 30, 2026. Amounts associated with physician practices are excluded.

4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.

5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less NCI expense plus permanent differences, and non-deductible interest expense.

6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

7. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues. Page 8

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Investor Contact Media Contact Will McDowell Olivia E. Nadler 469-893-2387 469-893-6352 [email protected] [email protected]

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non- GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

• Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, (12) income (loss) from divested and closed businesses (i.e., health plan businesses) and (13) revenue from contract termination. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.

• Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses), (7) revenue from contract termination and (8) the associated impact of these items on taxes and noncontrolling interests. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Free Cash Flow is defined by the Company as (1) net cash provided by (used in)

• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

• Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, (2) net cash provided by (used in) operating activities from discontinued operations and (3) cash received for contract termination defined above.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below. Page 10

Description Page Consolidated Statements of Operations 12 Consolidated Balance Sheets 14 Consolidated Statements of Cash Flows 15 Segment Reporting 16 Table #1–Reconciliations of 17 NetIncometoAdjusted Net Income Table #2–Reconciliations of Net Income 18 toAdjusted EBITDA Table #3–Reconciliations of Net Cash Provided by Operating Activities to Free 19 Cash Flow and Adjusted Free Cash Flow Table #4–Reconciliations of Outlook Net 20 Income to Outlook Adjusted Net Income Table #5–Reconciliations of Outlook Net 21 Income to Outlook Adjusted EBITDA Table #6–Reconciliations of Outlook Net Cash Provided byOperating Activities to 22 Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

(Dollars in September 30, December 31, millions) 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 2,674 $ 2,883 Accounts receivable 2,595 2,565 Inventories of supplies, 340 348 at cost Assets held for sale 62 62 Other current assets 2,757 1,991 Total current assets 8,428 7,849 Investments and other 3,958 2,883 assets Deferred income taxes 49 84 Property and equipment, at cost, less accumulated depreciation 6,290 6,315 and amortization Goodwill 11,641 11,198 Other intangible assets, at cost, less 1,226 1,348 accumulated amortization Total assets $ 31,592 $ 29,677 LIABILITIES AND EQUITY Current liabilities: Current portion of $ 164 $ 79 long-term debt Accounts payable 1,387 1,360 Accrued compensation and 873 858 benefits Professional and general liability 317 276 reserves Accrued interest payable 213 81 Income tax payable 22 — Other current liabilities 2,342 1,809 Total current liabilities 5,318 4,463 Long-term debt, net of 13,079 13,092 current portion Professional and general liability 979 951 reserves Defined benefit plan 238 245 obligations Deferred income taxes 529 240 Other long-term 1,855 1,713 liabilities Total liabilities 21,998 20,704 Commitments and contingencies Redeemable noncontrolling interests in 2,179 2,956 equity of consolidated subsidiaries Equity: Shareholders’ equity: Common stock 8 8 Additional paid-in capital 5,236 4,914 Accumulated other -178 -181 comprehensive loss Retained earnings 6,943 4,415 Common stock in treasury, -6,565 -4,936 at cost Total shareholders’ equity 5,444 4,220 Noncontrolling interests 1,971 1,797 Total equity 7,415 6,017 Total liabilities and $ 31,592 $ 29,677 equity

(Dollars in Nine Months Ended millions) September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 3,170 $ 1,723 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 661 632 amortization Deferred income tax 324 51 expense Stock-based 104 79 compensation expense Impairment and restructuring charges, 92 66 and acquisition-related costs Litigation and 36 34 investigation costs Net gains on sales, consolidation and -43 -4 deconsolidation of facilities Loss from early 5 — extinguishment of debt Equity in earnings of unconsolidated affiliates, net of -11 -13 distributions received Amortization of debt discount and debt 16 18 issuance costs Other items, net -11 -5 Changes in cash from operating assets and liabilities: Accounts receivable -11 68 Inventories and other 211 -58 current assets Income taxes 63 15 Accounts payable, accrued expenses and -1,042 237 other current liabilities Other long-term 46 50 liabilities Payments for restructuring charges, acquisition-related -103 -84 costs, and litigation costs and settlements Net cash provided by operating 3,507 2,809 activities Cash flows from investing activities: Purchases of property -546 -646 and equipment Purchases of businesses or joint venture -201 -266 interests, net of cash acquired Proceeds from sales of facilities and 11 18 other assets Proceeds from sales of marketable 66 74 securities and long-term investments Purchases of marketable securities and -122 -69 long-term investments Other items, net -26 3 Net cash used in -818 -886 investing activities Cash flows from financing activities: Repayments of -2,087 -90 borrowings Proceeds from 2,041 21 borrowings Repurchases of common -1,615 -1,188 stock Debt issuance costs -22 — Distributions paid to noncontrolling -614 -585 interests Proceeds from the sale of noncontrolling 33 27 interests Purchases of noncontrolling -583 -88 interests Repayments of advances from managed care — -33 payers Taxes paid related to net share settlement, net of proceeds from shares -84 -47 issued under stock‑based compensation plans Other items, net 33 16 Net cash used in -2,898 -1,967 financing activities Net decrease in cash and cash -209 -44 equivalents Cash and cash equivalents at 2,883 3,019 beginning of period Cash and cash equivalents at end of $ 2,674 $ 2,975 period Supplemental disclosures: Interest paid, net of capitalized $ -464 $ -499 interest Income tax payments, $ -493 $ -329 net

Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available to Common Shareholders

Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA

(Dollars in millions) 2026 Q3 YTD ───────────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 1,281 $ 3,507 activities Purchases of property and equipment -198 -546 Free cash flow $ 1,083 $ 2,961 Net cash used in investing activities $ -298 $ -818 Net cash used in financing activities $ -479 $ -2,898 Net cash provided by operating $ 1,281 $ 3,507 activities Less: Payments for restructuring charges, acquisition-related costs, and -19 -103 litigation costs and settlements Cash received for contract termination — 540 Adjusted net cash provided by operating 1,300 3,070 activities Purchases of property and equipment -198 -546 Adjusted free cash flow $ 1,102 $ 2,524

2025 (Dollars in millions) Q3 YTD ─────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 1,058 $ 2,809 activities Purchases of property and equipment -280 -646 Free cash flow $ 778 $ 2,163 Net cash used in investing activities $ -385 $ -886 Net cash used in financing activities $ -323 $ -1,967 Net cash provided by operating $ 1,058 $ 2,809 activities Less: Payments for restructuring charges, acquisition-related costs, and -3 -84 litigation costs and settlements Adjusted net cash provided by operating 1,061 2,893 activities Purchases of property and equipment -280 -646 Adjusted free cash flow $ 781 $ 2,247

Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available to Common Shareholders

(Dollars in millions, except per share amounts) FY 2026 Low High ────────────────────────────────────────────────────────────────────────────── Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Less: Revenue from contract termination 1,650 1,650 Impairment and restructuring charges, acquisition-related costs, and -180 -150 litigation costs and settlements(1) Net gains on sales, consolidation and 43 43 deconsolidation of facilities(2) Loss from early extinguishment of -5 -5 debt(2) Tax and noncontrolling interests impact -365 -370 of above items Adjusted net income available to common $ 1,830 $ 1,910 shareholders Diluted earnings per share $ 35.82 $ 37.08 Less: Revenue from contract termination 19.88 19.88 Impairment and restructuring charges, -2.17 -1.81 acquisition-related costs, and litigation costs and settlements Net gains on sales, consolidation and 0.52 0.52 deconsolidation of facilities Loss from early extinguishment of -0.06 -0.06 debt Tax and noncontrolling interests impact -4.40 -4.46 of above items Adjusted diluted earnings per $ 22.05 $ 23.01 share Weighted average dilutive shares 83,000 83,000 outstanding (in thousands) (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.

Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA

(Dollars in millions) FY 2026 Low High ────────────────────────────────────────────────────────────────────────────── Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Less: Net income available to noncontrolling -910 -960 interests Income tax expense -1,135 -1,170 Interest expense -825 -815 Loss from early extinguishment of -5 -5 debt(2) Other non-operating income, 150 200 net Net gains on sales, consolidation and 43 43 deconsolidation of facilities(2) Impairment and restructuring charges, acquisition-related costs, -180 -150 and litigation costs and settlements(1) Depreciation and -865 -915 amortization Revenue from contract 1,650 1,650 termination Adjusted EBITDA $ 5,050 $ 5,200 Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Net operating revenues $ 22,050 $ 22,450 Net income available to Tenet Healthcare Corporation common 13.5 % 13.7 % shareholders as a % of net operating revenues Adjusted EBITDA as a % of net operating 22.9 % 23.2 % revenues (Adjusted EBITDA margin) (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

FY 2026 (Dollars in millions) Low High ─────────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 3,885 $ 4,315 activities Purchases of property and equipment -700 -800 Free cash flow $ 3,185 $ 3,515 Net cash provided by operating $ 3,885 $ 4,315 activities Less: Payments for restructuring charges, acquisition-related costs and litigation -180 -150 costs and settlements(1) Cash received for contract termination 540 540 Adjusted net cash provided by operating 3,525 3,925 activities Purchases of property and equipment -700 -800 Adjusted free cash flow(2) $ 2,825 $ 3,125 (1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs or settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                Tenet Reports Strong Third Quarter 2026 Results;                
                                                                                
                                                                                
                         Raises 2026 Financial Outlook                          
                                                                                
                                                                                
  •                                                                             
                                                                                
Net income available to common shareholders in third quarter 2026 was $1.000
billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third
quarter 2025
                                                                                
  •                                                                             
                                                                                
                                                                                
  Adjusted diluted earnings per share                                           
                                                                                
                                                                                
  1                                                                             
                                                                                
increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third
quarter 2025
                                                                                
  •                                                                             
                                                                                
                                                                                
  Third quarter 2026 Consolidated Adjusted EBITDA                               
                                                                                
                                                                                
  1                                                                             
                                                                                
increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026
Adjusted EBITDA margin was 24.1%
                                                                                
  •                                                                             
                                                                                
Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased
9.1% over third quarter 2025
                                                                                
  •                                                                             
                                                                                
FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05
billion to $5.20 billion, a $195 million increase at the midpoint of the range;
FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of
$2.825 billion to $3.125 billion, a $100 million increase
                                                                                
  DALLAS — October 29, 2026 —                                                   
                                                                                
Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for
the quarter ended September 30, 2026.

"Our outperformance in the third quarter of 2026 was driven by sustained
strength in same-store revenue growth and effective expense management," said
Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on
patient-centered care, support for physician partners, technology-enabled growth
and operating initiatives continue to deliver strong margins and free cash
flow."
                                     Page 1                                     
Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:
                                                                                
             Three                              Nine                            
            Months                            Months                            
             Ended                             Ended                            
            Septe…                           Septem…                            
               30,                               30,                            
  ($ in                                                                         
  milli…                                                                        
  except      2026           2025               2026            2025            
  per                                                                           
  share                                                                         
  resul…                                                                        
  Net                                                                           
  opera…    $5,631                   $5,289  $16,627                    $15,7…  
  reven…                                                                        
  Net                                                                           
  income                                                                        
  avail…                                                                        
  to        $1,000                     $342   $2,528                    $1,036  
  Tenet                                                                         
  common                                                                        
  share…                                                                        
  Net                                                                           
  income                                                                        
  avail…                                                                        
  to                                                                            
  Tenet     $12.41                    $3.86   $30.08                    $11.28  
  common                                                                        
  share…                                                                        
  per                                                                           
  dilut…                                                                        
  share                                                                         
  Adjus…    $1,355                   $1,099   $3,821                    $3,383  
  EBITD…                                                                        
  Adjus…                                                                        
  dilut…                                                                        
  earni…              $6.64           $3.70             $17.50          $12.10  
  per                                                                           
  share1                                                                        
                                                                                
• Net income available to the Company’s common shareholders in third quarter
2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or
$3.86 per diluted share, in third quarter 2025.

• The Company had previously entered into certain agreements with CommonSpirit
Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the
parties agreed, in part, to the early conclusion and transition of our revenue
cycle management services by December 31, 2026, (collectively, the "RCM
Agreements").

• The transition of certain revenue cycle management services under the RCM
Agreements occurred during the third quarter of 2026 and will be substantially
complete by October 30, 2026. As a result of this revised timeline, during the
three months ended September 30, 2026, we recognized cumulative catch-up
adjustments that increased revenue from contract termination by $233 million and
net operating revenues by $97 million. These are timing-related adjustments and
as such, do not impact total or full year 2026 expectations for revenue from
contract termination or net operating revenues associated with the RCM
Agreements.

• In addition, we recognized a benefit of approximately $50 million during the
three months ended September 30, 2026 due to various transition activities,
including efficiencies from the revised timeline described above. This, combined
with the $97 million timing-related adjustment to net operating revenue
mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147
million in the third quarter of 2026.

• Adjusted EBITDA 1 was $1.355 billion in third quarter 2026 compared to $1.099
billion in third quarter 2025, reflecting strong same facility revenue growth
and disciplined expense management partially offset by unfavorable payer mix due
to lower exchange admissions. Results also include the $147 million favorable
net impact described above.
                                     Page 2                                     
Balance Sheet and Cash Flows

• Net cash flows provided by operating activities for the nine months ended
September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months
ended September 30, 2025.

• The Company generated adjusted free cash flow 1 of $2.524 billion for the nine
months ended September 30, 2026 versus $2.247 billion for the nine months ended
September 30, 2025.

• In the three months ended September 30, 2026, the Company repurchased 970,000
shares of common stock for $255 million. In the nine months ended September 30,
2026, the Company repurchased 7.99 million shares of common stock for $1.615
billion.

• In September 2026, the Company completed a private placement of $2.0 billion
in aggregate principal amount of newly issued 6.250% senior notes maturing in
2034. The Company used the net proceeds from the sale of the notes, after
payment of fees and expenses, to finance, together with cash on hand, the
redemption of all $1.5 billion aggregate principal amount then outstanding of
its 5.125% senior secured first lien notes due in 2027 and the partial
redemption of $500 million outstanding of its 6.125% senior notes due in 2028.

• The Company’s ratio of net debt to Adjusted EBITDA 1 was 2.11x at September
30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025.
                                     Page 3                                     
                                                                                
  Ambulatory Care (Ambulatory) Segment                                          
                                                                                
Tenet’s Ambulatory business segment is comprised of the operations of United
Surgical Partners International (USPI). As of September 30, 2026, USPI had
interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical
hospitals (seven consolidated) in 37 states.
                                                                                
         Thr…                                Nine                               
         Mon…                                Mon…                               
         End…                                End…                               
         Sep…                                Sep…                               
          30,                                 30,                               
  Am…                                                                           
  se…                                                                           
  re…    2026              2025              2026              2025             
  in                                                                            
  mi…                                                                           
  Re…                                                                           
  Net                                                                           
  op…                $1,…              $1,…  $4,…              $3,…             
  re…                                                                           
  Sa…                                                                           
  sy…                                                                           
  net                $2,…              $2,…              $6,…              $6…  
  pa…                                                                           
  se…                                                                           
  re…                                                                           
  Ch…                                                                           
  ve…                                                                           
  the                                                                           
  Pr…                                                                           
  Pe…                                                                           
  Sa…                                                                           
  sy…                                                                           
  net           4.5     %         8.3     %         5.1     %         7.5    %  
  pa…                                                                           
  se…                                                                           
  re…                                                                           
  Sa…                                                                           
  sy…                                                                           
  net                                                                           
  pa…           6.1     %         6.1     %         6.0     %         7.7    %  
  se…                                                                           
  re…                                                                           
  per                                                                           
  ca…                                                                           
  Sa…                                                                           
  sy…          -1.5     %         2.1     %        -0.8     %        -0.2    %  
  su…                                                                           
  ca…                                                                           
  Sa…                                                                           
  sy…                                                                           
  su…                                                                           
  ca…          -1.5     %         2.1     %        -0.8     %         0.4    %  
  on                                                                            
  sa…                                                                           
  day                                                                           
  ba…                                                                           
  Ad…                                                                           
  EB…                                                                           
  Ma…                                                                           
  and                                                                           
  NCI                                                                           
  Ad…    $537              $492              $1,…              $1,…             
  EB…                                                                           
  Ad…                                                                           
  EB…          39.2     %        38.6     %        38.3     %        38.7    %  
  ma…                                                                           
  Ad…                                                                           
  EB…                $327              $292              $948              $8…  
  le…                                                                           
  NCI                                                                           
                                                                                
• Third quarter 2026 net operating revenues increased 7.5% compared to third
quarter 2025 driven by strong growth in consolidated same-facility net patient
service revenues, acquisitions of facilities, and increased service lines.

• Surgical business same-facility system-wide net patient service revenues
increased 4.5% in third quarter 2026 compared to third quarter 2025, with cases
down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was
driven by higher acuity and favorable service mix.

• Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter
2025, due to strong growth in same-facility net patient service revenues,
disciplined expense management, and contributions from acquisitions.
                                     Page 4                                     
Hospital Operations and Services (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and
specialty hospitals, imaging centers, ancillary outpatient facilities, micro-
hospitals and physician practices. It also provides comprehensive end-to-end and
focused point services, including hospital and physician revenue cycle
management, patient communications and engagement support and value-based care
solutions.
                                                                                
         Thr…                                Nine                               
         Mon…                                Mon…                               
         End…                                End…                               
         Sep…                                Sep…                               
          30,                                 30,                               
  Ho…                                                                           
  se…                                                                           
  re…    2026              2025              2026              2025             
  in                                                                            
  mi…                                                                           
  Re…                                                                           
  Net                                                                           
  op…                $4,…              $4,…  $12…                          $1…  
  re…                                                                           
  Sa…                                                                           
  net                                                                           
  pa…                $3,…  $3,…                          $10…  $10…             
  se…                                                                           
  re…                                                                           
  Sa…                                                                           
  Vo…                                                                           
  Ch…                                                                           
  ve…                                                                           
  the                                                                           
  Pr…                                                                           
  Pe…                                                                           
  Ad…           2.8     %         1.5     %         1.8     %         2.5    %  
  Ad…           3.2     %         1.4     %         2.1     %         1.6    %  
  ad…                                                                           
  Ou…                                                                           
  vi…                                                                           
  (i…           0.1     %        -1.5     %        -0.9     %        -1.4    %  
  ou…                                                                           
  ER                                                                            
  vi…                                                                           
  Em…                                                                           
  Ro…                                                                           
  vi…           4.0     %        -2.0     %         0.9     %        -1.8    %  
  (i…                                                                           
  and                                                                           
  ou…                                                                           
  Ho…          -1.1     %         0.7     %        -0.9     %        -0.8    %  
  su…                                                                           
  Ad…                                                                           
  EB…                                                                           
  Ad…                $818  $607              $2,…              $1,…             
  EB…                                                                           
  Ad…                                                                           
  EB…          19.2     %        15.1     %        18.0     %        16.1    %  
  ma…                                                                           
                                                                                
• Third quarter 2026 net operating revenues increased 6.1% from third quarter
2025 driven by an increase in adjusted admissions as well as continued pricing
strength, partially offset by unfavorable payer mix due to lower exchange
admissions. In addition, third quarter 2026 net operating revenues include a
timing-related benefit of $97 million associated with the RCM Agreements as
described on page 2.

• Same-hospital net patient service revenue per adjusted admission increased
0.2% year-over-year for third quarter 2026 primarily due to strength in
commercial employer net patient revenues offset by unfavorable payer mix related
to lower exchange admissions.

• Adjusted EBITDA in third quarter 2026 was $818 million compared to $607
million in third quarter 2025, reflecting strong growth in same-hospital revenue
and disciplined expense management, partially offset by unfavorable payer mix
due to lower exchange admissions. Results also include the net favorable impact
of $147 million from transition activities described on page 2.

• In the third quarter of 2026, the Hospital segment recognized a $32 million
favorable pre-tax impact associated with additional Medicaid supplemental
revenues related to prior years. Third quarter 2025 results included a $38
million favorable pre-tax impact for additional Medicaid supplemental revenues
related to prior years.
                                     Page 5                                     
                                                                                
  2026 Outlook                                                                  
                                                                                
                                                                                
  1                                                                             
                                                                                
Tenet’s Outlook for full year 2026 (consolidated and by segment) follows.
Contract termination revenue recognized from the early conclusion of the RCM
Agreements is not included in net operating revenues.
                                                                            
  CONSOLIDATED($ in millions, except per share          FY 2026 Outlook     
  amounts)                                                                  
  Net operating revenues7                               $22,050 to $22,450  
  Net income available to Tenet common shareholders     $2,973 to $3,078    
  Adjusted EBITDA                                       $5,050 to $5,200    
  Adjusted EBITDA margin                                22.9% to 23.2%      
  Diluted income per common share                       $35.82 to $37.08    
  Adjusted net income                                   $1,830 to $1,910    
  Adjusted diluted earnings per share                   $22.05 to $23.01    
  Equity in earnings of unconsolidated affiliates       $265 to $275        
  Depreciation and amortization                         $865 to $915        
  Interest expense                                      $815 to $825        
  Income tax expense5                                   $1,135 to $1,170    
  Net income available to NCI                           $910 to $960        
  Weighted average diluted common shares                ~83 million         
  Net cash provided by operating activities             $3,885 to $4,315    
  Adjusted net cash provided by operating activities    $3,525 to $3,925    
  Capital expenditures                                  $700 to $800        
  Free cash flow                                        $3,185 to $3,515    
  Adjusted free cash flow                               $2,825 to $3,125    
  NCI cash distributions                                $900 to $970        
                                                                            
                                     Page 6                                     
                                                          
  Ambulatory Segment($ in millions)     FY 2026 Outlook   
  Net operating revenues                $5,530 to $5,670  
  Adjusted EBITDA                       $2,160 to $2,220  
  NCI                                   $865 to $895      
  Adjusted EBITDA less NCI              $1,295 to $1,325  
  Changes versus prior year6:                             
  Same-facility system-wide revenues    Up 3.0% to 6.0%   
                                                          
                                                         
  Hospital Segment($ in millions)    FY 2026 Outlook     
  Net operating revenues7            $16,520 to $16,780  
  Adjusted EBITDA                    $2,890 to $2,980    
  NCI                                $45 to $65          
  Changes versus prior year6:                            
  Inpatient admissions               Up 1.0% to 2.0%     
  Adjusted admissions                Up 1.0% to 2.0%     
                                                         
                                                                                
  Management’s Webcast Discussion of Results                                    
                                                                                
Tenet management will discuss the Company’s third quarter 2026 results in a
webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on
October 29, 2026. Investors can access the webcast through the Company’s website
at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of
this earnings press release, and a related supplemental financial disclosures
document will be available on the Company’s Investor Relations website on
October 29, 2026.
                                     Page 7                                     
                                                                                
  Cautionary Statement                                                          
                                                                                
This release contains “forward-looking statements” - that is, statements that
relate to future, not past, events. In this context, forward-looking statements
often address the Company’s expected future business and financial performance
and financial condition, and often contain words such as “expect,” “anticipate,”
“assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,”
“predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking
statements by their nature address matters that are, to different degrees,
uncertain. Particular uncertainties that could cause the Company’s actual
results to be materially different than those expressed in the Company’s
forward-looking statements include, but are not limited to the factors disclosed
under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the
year ended December 31, 2025 and other filings with the Securities and Exchange
Commission .
                                                                                
  Footnotes                                                                     
                                                                                
1. Tables and discussions throughout this earnings release include certain
financial measures, including those related to our full year 2026 Outlook, that
are not in accordance with accounting principles generally accepted in the
United States of America (GAAP). Reconciliations of GAAP measures to the
Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the
end of this earnings release. Management’s reasoning for the use of these non-
GAAP measures and descriptions of the various non-GAAP measures are included in
the Non-GAAP Financial Measures section of this earnings release.

2. Same-facility system-wide revenues and statistical information include the
results of the facilities in which the Ambulatory segment has an investment that
are not consolidated by Tenet. To help analyze the segment’s results of
operations, management uses system-wide measures, which include revenues and
cases of both consolidated and unconsolidated facilities.

3. For 2026, same-hospital revenues and statistical data include those for
hospitals and hospital-affiliated outpatient centers operated by the Company’s
Hospital segment continuously from January 1, 2025 through September 30, 2026.
Amounts associated with physician practices are excluded.

4. Adjusted admissions represent actual patient admissions adjusted to include
outpatient services provided by facilities in our Hospital segment by
multiplying actual patient admissions by the sum of gross inpatient revenues and
outpatient revenues, then dividing that result by gross inpatient revenues.

5. Income tax expense is calculated by multiplying 24% (the federal corporate
tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income
less NCI expense plus permanent differences, and non-deductible interest
expense.

6. Change versus prior year is presented on a same-facility system-wide basis
for USPI Ambulatory surgical cases and on a same-hospital basis for hospital
statistics.

7. Contract termination revenue recognized from the early conclusion of the RCM
Agreements is not included in net operating revenues.
                                     Page 8                                     
                                                                                
  About Tenet Healthcare                                                        
                                                                                
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services
company headquartered in Dallas. Our care delivery network includes United
Surgical Partners International, the largest ambulatory platform in the country,
which operates ambulatory surgery centers and surgical hospitals. We also
operate a national portfolio of acute care and specialty hospitals, other
outpatient facilities, a network of leading employed physicians and a global
business center in Manila, Philippines. Our Conifer Health Solutions subsidiary
provides revenue cycle management and value-based care services to hospitals,
health systems, physician practices, employers and other clients. Across the
Tenet enterprise, we are united by our mission to deliver quality, compassionate
care in the communities we serve. For more information, please visit
www.tenethealth.com.
                                                                                
  Contact Information                                                           
                                                                                
                                                                      
  Investor Contact                    Media Contact                   
  Will McDowell                       Olivia E. Nadler                
  469-893-2387                        469-893-6352                    
  [email protected]    [email protected]  
                                                                      
                                     Page 9                                     
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
The Company believes the non-GAAP measures described below are useful to
investors and analysts because they present additional information on the
Company’s financial performance. Investors, analysts, Company management and the
Company’s Board of Directors utilize these non-GAAP measures, in addition to
GAAP measures, to track the Company’s financial and operating performance and
compare the Company’s performance to its peer companies, which use similar non-
GAAP financial measures in their presentations and earnings releases. The Human
Resources Committee of the Company’s Board of Directors also uses certain of
these measures to evaluate management’s performance for the purpose of
determining incentive compensation. Additional information regarding the purpose
and utility of specific non-GAAP measures used in this release is set forth
below.

• Adjusted EBITDA is defined by the Company as net income available (loss
attributable) to Tenet common shareholders before (1) the cumulative effect of
changes in accounting principles, (2) net loss attributable (income available)
to noncontrolling interests, (3) income (loss) from discontinued operations, net
of tax, (4) income tax benefit (expense), (5) gain (loss) from early
extinguishment of debt, (6) other non-operating income (expense), net, (7)
interest expense, (8) litigation and investigation benefit (costs), net of
insurance recoveries, (9) net gains (losses) on sales, consolidation and
deconsolidation of facilities, (10) impairment and restructuring charges and
acquisition-related costs, (11) depreciation and amortization, (12) income
(loss) from divested and closed businesses (i.e., health plan businesses) and
(13) revenue from contract termination. Revenue from contract termination
represents the present value of the $1.9 billion of consideration related to the
early termination of Conifer’s revenue cycle services agreement with
CommonSpirit (as further described in the Company’s Form 8-K dated February 2,
2026), net of amortization of an associated contract asset. Litigation and
investigation benefit (costs) excluded do not include ordinary course of
business malpractice and other litigation and related expenses.

• Adjusted diluted earnings (loss) per share is defined by the Company as
Adjusted net income available (loss attributable) to Tenet common shareholders,
divided by the weighted average diluted shares outstanding in the reporting
period.

• Adjusted net income available (loss attributable) to Tenet common shareholders
is defined by the Company as net income available (loss attributable) to Tenet
common shareholders before (1) income (loss) from discontinued operations, net
of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and
investigation benefit (costs), net of insurance recoveries, (4) net gains
(losses) on sales, consolidation and deconsolidation of facilities, (5)
impairment and restructuring charges and acquisition-related costs, (6) income
(loss) from divested and closed businesses (i.e., health plan businesses), (7)
revenue from contract termination and (8) the associated impact of these items
on taxes and noncontrolling interests. Revenue from contract termination
represents the present value of the $1.9 billion of consideration related to the
early termination of Conifer’s revenue cycle services agreement with
CommonSpirit (as further described in the Company’s Form 8-K dated February 2,
2026), net of amortization of an associated contract asset. Litigation and
investigation benefit (costs) excluded do not include ordinary course of
business malpractice and other litigation and related expenses.

• Free Cash Flow is defined by the Company as (1) net cash provided by (used in)
operating activities, less (2) purchases of property and equipment.

• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash
provided by (used in) operating activities, less (2) purchases of property and
equipment.

• Adjusted net cash provided by (used in) operating activities is defined by the
Company as cash provided by (used in) operating activities prior to (1) payments
for restructuring charges, acquisition-related costs and litigation costs and
settlements, (2) net cash provided by (used in) operating activities from
discontinued operations and (3) cash received for contract termination defined
above.

The Company believes that Adjusted EBITDA is a useful measure, in part, because
certain investors and analysts use both historical and projected Adjusted
EBITDA, in addition to other GAAP and non-GAAP measures, as factors in
determining the estimated fair value of shares of the Company’s common stock.
Company management also regularly reviews the Adjusted EBITDA performance for
each operating segment. The Company does not use Adjusted EBITDA to measure
liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free
Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from
the Company’s operations. The Company believes these measures are useful to
investors in evaluating its ability to fund distributions paid to noncontrolling
interests or for acquisitions, purchasing equity interests in joint ventures or
repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures
reported by other companies. Because these measures exclude many items that are
included in the Company’s financial statements, they do not provide a complete
measure of the Company’s operating performance. For example, the Company’s
definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other
important uses of cash including (1) cash used to purchase businesses or joint
venture interests, or (2) any items that are classified as Cash Flows from
Financing Activities on the Company’s Consolidated Statement of Cash Flows,
including items such as (i) cash used to repay borrowings, or (ii) distributions
paid to noncontrolling interests. Accordingly, investors are encouraged to use
GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to
above to the most comparable GAAP financial measures in Tables #1 - 6 below.
                                    Page 10                                     
                                                                                
                          Tenet Healthcare Corporation                          
                                                                                
                                                                                
                    Financial Statements and Reconciliations                    
                                                                                
                                                                                
                         Third Quarter Earnings Release                         
                                                                                
                                                                                
  Table of Contents                                                             
                                                                                
                                                          
  Description                                       Page  
  Consolidated Statements of Operations       12          
  Consolidated Balance Sheets                 14          
  Consolidated Statements of Cash Flows       15          
  Segment Reporting                           16          
  Table #1–Reconciliations of                 17          
  NetIncometoAdjusted Net Income                          
  Table #2–Reconciliations of Net Income      18          
  toAdjusted EBITDA                                       
  Table #3–Reconciliations of Net Cash                    
  Provided by Operating Activities to Free    19          
  Cash Flow and Adjusted Free Cash Flow                   
  Table #4–Reconciliations of Outlook Net     20          
  Income to Outlook Adjusted Net Income                   
  Table #5–Reconciliations of Outlook Net     21          
  Income to Outlook Adjusted EBITDA                       
  Table #6–Reconciliations of Outlook Net                 
  Cash Provided byOperating Activities to     22          
  Outlook Free Cash Flow and Outlook                      
  Adjusted Free Cash Flow                                 
                                                          
                                    Page 11                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                     CONSOLIDATED STATEMENTS OF OPERATIONS                      
                                                                                
                                  (Unaudited)                                   
                                                                                
  …                                                                             
  …                                                                             
  …          T…                                                                 
  …          M…                                                                 
  …          E…                                                                 
  …          S…                                                                 
  …    2…    3…        %           2…                %            C…            
 ────────────────────────────────────────────────────────────────────────────── 
  …                                                                             
  …          $   5…         1…  %        $  5,…           10…  %        6.5  %  
  …                                                                             
  …                                                                             
  …              6…         1…  %             —             —  %        10…  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              64         1…  %            64           1.2  %          —  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              2…         3…  %           2,…           41…  %        -1…  %  
  …                                                                             
  …                                                                             
  …              9…         1…  %           931           17…  %        5.6  %  
  …                                                                             
  …              1…         2…  %           1,…           21…  %        5.8  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …              2…         3…  %           218           4.1  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              37         0…  %            23           0.4  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …               6         0…  %           -11           -0…  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              -9         -…  %           -20           -0…  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              1…         3…  %           889           16…  %                
  …                                                                             
  …              -…                         -2…                                 
  …                                                                             
  …                                                                             
  …              37                          29                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              -5                           —                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              1…                         712                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …              -…                         -1…                                 
  …                                                                             
  …              1…                         579                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              2…                         237                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …          $   1…                      $  342                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …          $   1…                      $  3.…                                 
  …          $   1…                      $  3.…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              8…                              8…                             
  …              8…                              8…                             
                                                                                
                                    Page 12                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                     CONSOLIDATED STATEMENTS OF OPERATIONS                      
                                                                                
                                  (Unaudited)                                   
                                                                                
  …                                                                             
  …                                                                             
  …          N…                                                                 
  …          M…                                                                 
  …          E…                                                                 
  …          S…                                                                 
  …    2…    3…        %           2…                %            C…            
 ────────────────────────────────────────────────────────────────────────────── 
  …                                                                             
  …          $   1…         1…  %        $  15…           10…  %        5.3  %  
  …                                                                             
  …                                                                             
  …              1…         8…  %             —             —  %        10…  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              1…         1…  %           181           1.1  %        -0…  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              6…         3…  %           6,…           41…  %        1.5  %  
  …                                                                             
  …                                                                             
  …              2…         1…  %           2,…           17…  %        5.7  %  
  …                                                                             
  …              3…         2…  %           3,…           21…  %        4.6  %  
  …                                                                             
  …                                                                             
  …                                                                             
  …              6…         4…  %           632           4.0  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              92         0…  %            66           0.4  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              36         0…  %            34           0.2  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              -…         -…  %            -4             —  %                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              4…         2…  %           2,…           16…  %                
  …                                                                             
  …              -…                         -6…                                 
  …                                                                             
  …                                                                             
  …              1…                          80                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              -5                           —                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              4…                         2,…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …              -…                         -3…                                 
  …                                                                             
  …              3…                         1,…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              6…                         687                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …          $   2…                      $  1,…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …          $   3…                      $  11…                                 
  …          $   3…                      $  11…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …              8…                              9…                             
  …              8…                              9…                             
                                                                                
                                    Page 13                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                          CONSOLIDATED BALANCE SHEETS                           
                                                                                
                                  (Unaudited)                                   
                                                                                
                              (Dollars in     September 30,       December 31,  
                              millions)                2026               2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets:                                                               
  Cash and cash equivalents                $          2,674    $         2,883  
  Accounts receivable                                 2,595              2,565  
  Inventories of supplies,                              340                348  
  at cost                                                                       
  Assets held for sale                                   62                 62  
  Other current assets                                2,757              1,991  
  Total current assets                                8,428              7,849  
  Investments and other                               3,958              2,883  
  assets                                                                        
  Deferred income taxes                                  49                 84  
  Property and equipment, at                                                    
  cost, less                                                                    
  accumulated depreciation                            6,290              6,315  
  and                                                                           
  amortization                                                                  
  Goodwill                                           11,641             11,198  
  Other intangible assets,                                                      
  at cost, less                                       1,226              1,348  
  accumulated amortization                                                      
  Total assets                             $         31,592    $        29,677  
  LIABILITIES AND EQUITY                                                        
  Current liabilities:                                                          
  Current portion of                       $            164    $            79  
  long-term debt                                                                
  Accounts payable                                    1,387              1,360  
  Accrued compensation and                              873                858  
  benefits                                                                      
  Professional and general                                                      
  liability                                             317                276  
  reserves                                                                      
  Accrued interest payable                              213                 81  
  Income tax payable                                     22                  —  
  Other current liabilities                           2,342              1,809  
  Total current liabilities                           5,318              4,463  
  Long-term debt, net of                             13,079             13,092  
  current portion                                                               
  Professional and general                                                      
  liability                                             979                951  
  reserves                                                                      
  Defined benefit plan                                  238                245  
  obligations                                                                   
  Deferred income taxes                                 529                240  
  Other long-term                                     1,855              1,713  
  liabilities                                                                   
  Total liabilities                                  21,998             20,704  
  Commitments and                                                               
  contingencies                                                                 
  Redeemable noncontrolling                                                     
  interests in                                        2,179              2,956  
  equity of consolidated                                                        
  subsidiaries                                                                  
  Equity:                                                                       
  Shareholders’ equity:                                                         
  Common stock                                            8                  8  
  Additional paid-in capital                          5,236              4,914  
  Accumulated other                                    -178               -181  
  comprehensive loss                                                            
  Retained earnings                                   6,943              4,415  
  Common stock in treasury,                          -6,565             -4,936  
  at cost                                                                       
  Total shareholders’ equity                          5,444              4,220  
  Noncontrolling interests                            1,971              1,797  
  Total equity                                        7,415              6,017  
  Total liabilities and                    $         31,592    $        29,677  
  equity                                                                        
                                                                                
                                    Page 14                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                     CONSOLIDATED STATEMENTS OF CASH FLOWS                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                           (Dollars in  Nine Months Ended                       
                           millions)    September 30,        2026         2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                            $                   3,170    $   1,723  
  Adjustments to                                                                
  reconcile net income to                                                       
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                            661          632  
  amortization                                                                  
  Deferred income tax                                         324           51  
  expense                                                                       
  Stock-based                                                 104           79  
  compensation expense                                                          
  Impairment and                                                                
  restructuring charges,                                       92           66  
  and acquisition-related                                                       
  costs                                                                         
  Litigation and                                               36           34  
  investigation costs                                                           
  Net gains on sales,                                                           
  consolidation and                                           -43           -4  
  deconsolidation of                                                            
  facilities                                                                    
  Loss from early                                               5            —  
  extinguishment of debt                                                        
  Equity in earnings of                                                         
  unconsolidated                                                                
  affiliates, net of                                          -11          -13  
  distributions                                                                 
  received                                                                      
  Amortization of debt                                                          
  discount and debt                                            16           18  
  issuance costs                                                                
  Other items, net                                            -11           -5  
  Changes in cash from                                                          
  operating assets                                                              
  and liabilities:                                                              
  Accounts receivable                                         -11           68  
  Inventories and other                                       211          -58  
  current assets                                                                
  Income taxes                                                 63           15  
  Accounts payable,                                                             
  accrued expenses and                                     -1,042          237  
  other current                                                                 
  liabilities                                                                   
  Other long-term                                              46           50  
  liabilities                                                                   
  Payments for                                                                  
  restructuring charges,                                                        
  acquisition-related                                        -103          -84  
  costs, and                                                                    
  litigation costs and                                                          
  settlements                                                                   
  Net cash provided by                                                          
  operating                                                 3,507        2,809  
  activities                                                                    
  Cash flows from                                                               
  investing activities:                                                         
  Purchases of property                                      -546         -646  
  and equipment                                                                 
  Purchases of businesses                                                       
  or joint venture                                           -201         -266  
  interests, net of cash                                                        
  acquired                                                                      
  Proceeds from sales of                                                        
  facilities and                                               11           18  
  other assets                                                                  
  Proceeds from sales of                                                        
  marketable                                                   66           74  
  securities and                                                                
  long-term investments                                                         
  Purchases of marketable                                                       
  securities and                                             -122          -69  
  long-term investments                                                         
  Other items, net                                            -26            3  
  Net cash used in                                           -818         -886  
  investing activities                                                          
  Cash flows from                                                               
  financing activities:                                                         
  Repayments of                                            -2,087          -90  
  borrowings                                                                    
  Proceeds from                                             2,041           21  
  borrowings                                                                    
  Repurchases of common                                    -1,615       -1,188  
  stock                                                                         
  Debt issuance costs                                         -22            —  
  Distributions paid to                                                         
  noncontrolling                                             -614         -585  
  interests                                                                     
  Proceeds from the sale                                                        
  of noncontrolling                                            33           27  
  interests                                                                     
  Purchases of                                                                  
  noncontrolling                                             -583          -88  
  interests                                                                     
  Repayments of advances                                                        
  from managed care                                             —          -33  
  payers                                                                        
  Taxes paid related to                                                         
  net share                                                                     
  settlement, net of                                                            
  proceeds from shares                                        -84          -47  
  issued under                                                                  
  stock‑based                                                                   
  compensation                                                                  
  plans                                                                         
  Other items, net                                             33           16  
  Net cash used in                                         -2,898       -1,967  
  financing activities                                                          
  Net decrease in cash                                                          
  and cash                                                   -209          -44  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents at                                            2,883        3,019  
  beginning                                                                     
  of period                                                                     
  Cash and cash                                                                 
  equivalents at end of                 $                   2,674    $   2,975  
  period                                                                        
  Supplemental                                                                  
  disclosures:                                                                  
  Interest paid, net of                                                         
  capitalized                           $                    -464    $    -499  
  interest                                                                      
  Income tax payments,                  $                    -493    $    -329  
  net                                                                           
                                                                                
                                    Page 15                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                               SEGMENT REPORTING                                
                                                                                
                                  (Unaudited)                                   
                                                                                
  (Do…    Three                                Nine                             
  in      Mont…                                Mon…                             
  mil…    Ended                                End…                             
  Net     Sept…                                Sep…                             
  ope…    30,                                  30,                              
  rev…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Amb…    $      1,371       $     1,275       $     4,079       $     3,7…     
  Care                                                                          
  Hos…                                                                          
  Ope…           4,260             4,014             12,5…             12,…     
  and                                                                           
  Ser…                                                                          
  Tot…    $      5,631       $     5,289       $     16,6…       $     15,…     
  Equ…                                                                          
  in                                                                            
  ear…                                                                          
  of                                                                            
  unc…                                                                          
  aff…                                                                          
  Amb…    $         64       $        63       $       179       $      176     
  Care                                                                          
  Hos…                                                                          
  Ope…               —                 1                 1                5     
  and                                                                           
  Ser…                                                                          
  Tot…    $         64       $        64       $       180       $      181     
  Adj…                                                                          
  EBI…                                                                          
  Amb…    $        537       $       492       $     1,563       $     1,4…     
  Care                                                                          
  Hos…                                                                          
  Ope…             818               607             2,258             1,9…     
  and                                                                           
  Ser…                                                                          
  Tot…    $      1,355       $     1,099       $     3,821       $     3,3…     
  Adj…                                                                          
  EBI…                                                                          
  mar…                                                                          
  Amb…            39.2  %           38.6  %           38.3  %          38.7  %  
  Care                                                                          
  Hos…                                                                          
  Ope…            19.2  %           15.1  %           18.0  %          16.1  %  
  and                                                                           
  Ser…                                                                          
  Tot…            24.1  %           20.8  %           23.0  %          21.4  %  
  Cap…                                                                          
  exp…                                                                          
  Amb…    $         40       $        38       $       110       $       90     
  Care                                                                          
  Hos…                                                                          
  Ope…             158               242               436              556     
  and                                                                           
  Ser…                                                                          
  Tot…    $        198       $       280       $       546       $      646     
                                                                                
                                    Page 16                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
     Table #1 – Reconciliations of Net Income Available to Tenet Healthcare     
   Corporation Common Shareholders to Adjusted Net Income Available to Common   
                                  Shareholders                                  
                                                                                
                                  (Unaudited)                                   
                                                                                
  (Doll…                                                                        
  in                                                                            
  milli…                                                                        
  except    Three                              Nine                             
  per       Months                             Months                           
  share     Ended    Septe…                    Ended    Septe…                  
  amoun…    2026        30,    2025            2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  income                                                                        
  avail…                                                                        
  to                                                                            
  Tenet     $         1,000    $        342    $         2,528    $      1,036  
  Healt…                                                                        
  Corpo…                                                                        
  common                                                                        
  share…                                                                        
  Less:                                                                         
  Reven…                                                                        
  from                  646               —              1,472               —  
  contr…                                                                        
  termi…                                                                        
  Impai…                                                                        
  and                                                                           
  restr…                                                                        
  charg…                -37             -23                -92             -66  
  and                                                                           
  acqui…                                                                        
  costs                                                                         
  Litig…                                                                        
  and                                                                           
  inves…                 -6              11                -36             -34  
  benef…                                                                        
  (cost…                                                                        
  Net                                                                           
  gains                                                                         
  on                                                                            
  sales,                                                                        
  conso…                  9              20                 43               4  
  and                                                                           
  decon…                                                                        
  of                                                                            
  facil…                                                                        
  Loss                                                                          
  from                                                                          
  early                  -5               —                 -5               —  
  extin…                                                                        
  of                                                                            
  debt                                                                          
  Tax                                                                           
  and                                                                           
  nonco…                                                                        
  inter…               -142               6               -325              21  
  impact                                                                        
  of                                                                            
  above                                                                         
  items                                                                         
  Adjus…                                                                        
  net                                                                           
  income                                                                        
  avail…    $           535    $        328    $         1,471    $      1,111  
  to                                                                            
  common                                                                        
  share…                                                                        
  Dilut…                                                                        
  earni…    $         12.41    $       3.86    $         30.08    $      11.28  
  per                                                                           
  share                                                                         
  Less:                                                                         
  Reven…                                                                        
  from                 8.01               —              17.51               —  
  contr…                                                                        
  termi…                                                                        
  Impai…                                                                        
  and                                                                           
  restr…                                                                        
  charg…              -0.46           -0.26              -1.09           -0.72  
  and                                                                           
  acqui…                                                                        
  costs                                                                         
  Litig…                                                                        
  and                                                                           
  inves…              -0.07            0.12              -0.43           -0.37  
  benef…                                                                        
  (cost…                                                                        
  Net                                                                           
  gains                                                                         
  on                                                                            
  sales,                                                                        
  conso…               0.11            0.23               0.51            0.04  
  and                                                                           
  decon…                                                                        
  of                                                                            
  facil…                                                                        
  Loss                                                                          
  from                                                                          
  early               -0.06               —              -0.06               —  
  extin…                                                                        
  of                                                                            
  debt                                                                          
  Tax                                                                           
  and                                                                           
  nonco…                                                                        
  inter…              -1.76            0.07              -3.86            0.23  
  impact                                                                        
  of                                                                            
  above                                                                         
  items                                                                         
  Adjus…                                                                        
  dilut…                                                                        
  earni…    $          6.64    $       3.70    $         17.50    $      12.10  
  per                                                                           
  share                                                                         
  Weigh…                                                                        
  avera…                                                                        
  basic                                                                         
  shares             80,134          87,951             83,486          91,109  
  outst…                                                                        
  (in                                                                           
  thous…                                                                        
  Weigh…                                                                        
  avera…                                                                        
  dilut…                                                                        
  shares             80,600          88,610             84,053          91,805  
  outst…                                                                        
  (in                                                                           
  thous…                                                                        
                                                                                
                                    Page 17                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
     Table #2 – Reconciliations of Net Income Available to Tenet Healthcare     
               Corporation Common Shareholders to Adjusted EBITDA               
                                                                                
                                  (Unaudited)                                   
                                                                                
          Three                                Nine                             
  (Do…    Mont…                                Mon…                             
  in      Ended  Sept…                         End…  Sept…                      
  mil…    2026     30,       2025              2026    30,       2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inc…                                                                          
  ava…                                                                          
  to                                                                            
  Ten…    $      1,000       $       342       $     2,528       $     1,0…     
  Hea…                                                                          
  Cor…                                                                          
  com…                                                                          
  sha…                                                                          
  Les…                                                                          
  Net                                                                           
  inc…                                                                          
  ava…            -219              -237              -642             -687     
  to                                                                            
  non…                                                                          
  int…                                                                          
  Net            1,219               579             3,170             1,7…     
  inc…                                                                          
  Inc…                                                                          
  tax             -360              -133              -881             -396     
  exp…                                                                          
  Loss                                                                          
  from                                                                          
  ear…              -5                 —                -5                —     
  ext…                                                                          
  of                                                                            
  debt                                                                          
  Oth…                                                                          
  non…              37                29               121               80     
  inc…                                                                          
  net                                                                           
  Int…            -203              -206              -612             -616     
  exp…                                                                          
  Ope…           1,750               889             4,547             2,6…     
  inc…                                                                          
  Rev…                                                                          
  from             646                 —             1,472                —     
  con…                                                                          
  ter…                                                                          
  Dep…                                                                          
  and             -217              -218              -661             -632     
  amo…                                                                          
  Imp…                                                                          
  and                                                                           
  res…                                                                          
  cha…             -37               -23               -92              -66     
  and                                                                           
  acq…                                                                          
  cos…                                                                          
  Lit…                                                                          
  and                                                                           
  inv…              -6                11               -36              -34     
  ben…                                                                          
  (co…                                                                          
  Net                                                                           
  gai…                                                                          
  on                                                                            
  sal…                                                                          
  con…               9                20                43                4     
  and                                                                           
  dec…                                                                          
  of                                                                            
  fac…                                                                          
  Adj…    $      1,355       $     1,099       $     3,821       $     3,3…     
  EBI…                                                                          
  Net                                                                           
  ope…    $      5,631       $     5,289       $     16,6…       $     15,…     
  rev…                                                                          
  Net                                                                           
  inc…                                                                          
  ava…                                                                          
  to                                                                            
  Ten…                                                                          
  Hea…                                                                          
  Cor…                                                                          
  com…            17.8  %            6.5  %           15.2  %           6.6  %  
  sha…                                                                          
  as a                                                                          
  %                                                                             
  of                                                                            
  net                                                                           
  ope…                                                                          
  rev…                                                                          
  Adj…                                                                          
  EBI…                                                                          
  as a                                                                          
  % of                                                                          
  net             24.1  %           20.8  %           23.0  %          21.4  %  
  ope…                                                                          
  rev…                                                                          
  (Ad…                                                                          
  EBI…                                                                          
  mar…                                                                          
                                                                                
                                    Page 18                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
   Table #3 – Reconciliations of Net Cash Provided by Operating Activities to   
                                                                                
                   Free Cash Flow and Adjusted Free Cash Flow                   
                                                                                
                                  (Unaudited)                                   
                                                                               
  (Dollars in millions)                      2026    Q3           YTD          
 ───────────────────────────────────────────────────────────────────────────── 
  Net cash provided by operating                     $   1,281    $     3,507  
  activities                                                                   
  Purchases of property and equipment                     -198           -546  
  Free cash flow                                     $   1,083    $     2,961  
  Net cash used in investing activities              $    -298    $      -818  
  Net cash used in financing activities              $    -479    $    -2,898  
  Net cash provided by operating                     $   1,281    $     3,507  
  activities                                                                   
  Less:                                                                        
  Payments for restructuring charges,                                          
  acquisition-related costs, and                           -19           -103  
  litigation costs and settlements                                             
  Cash received for contract termination                     —            540  
  Adjusted net cash provided by operating                1,300          3,070  
  activities                                                                   
  Purchases of property and equipment                     -198           -546  
  Adjusted free cash flow                            $   1,102    $     2,524  
                                                                               
                                                                         
                                             2025                        
  (Dollars in millions)                      Q3             YTD          
 ─────────────────────────────────────────────────────────────────────── 
  Net cash provided by operating             $     1,058    $     2,809  
  activities                                                             
  Purchases of property and equipment               -280           -646  
  Free cash flow                             $       778    $     2,163  
  Net cash used in investing activities      $      -385    $      -886  
  Net cash used in financing activities      $      -323    $    -1,967  
  Net cash provided by operating             $     1,058    $     2,809  
  activities                                                             
  Less:                                                                  
  Payments for restructuring charges,                                    
  acquisition-related costs, and                      -3            -84  
  litigation costs and settlements                                       
  Adjusted net cash provided by operating          1,061          2,893  
  activities                                                             
  Purchases of property and equipment               -280           -646  
  Adjusted free cash flow                    $       781    $     2,247  
                                                                         
                                    Page 19                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
 Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare 
  Corporation Common Shareholders to Outlook Adjusted Net Income Available to   
                              Common Shareholders                               
                                                                                
                                  (Unaudited)                                   
                                                                                
  (Dollars in millions, except per                                              
  share                                                                         
  amounts)                              FY 2026    Low            High          
 ────────────────────────────────────────────────────────────────────────────── 
  Net income available to Tenet                                                 
  Healthcare                                       $     2,973    $      3,078  
  Corporation common shareholders                                               
  Less:                                                                         
  Revenue from contract termination                      1,650           1,650  
  Impairment and restructuring                                                  
  charges,                                                                      
  acquisition-related costs, and                          -180            -150  
  litigation costs and                                                          
  settlements(1)                                                                
  Net gains on sales, consolidation                                             
  and                                                       43              43  
  deconsolidation of facilities(2)                                              
  Loss from early extinguishment of                         -5              -5  
  debt(2)                                                                       
  Tax and noncontrolling interests                                              
  impact                                                  -365            -370  
  of above items                                                                
  Adjusted net income available to                                              
  common                                           $     1,830    $      1,910  
  shareholders                                                                  
  Diluted earnings per share                       $     35.82    $      37.08  
  Less:                                                                         
  Revenue from contract termination                      19.88           19.88  
  Impairment and restructuring                                                  
  charges,                                               -2.17           -1.81  
  acquisition-related costs, and                                                
  litigation costs and settlements                                              
  Net gains on sales, consolidation                                             
  and                                                     0.52            0.52  
  deconsolidation of facilities                                                 
  Loss from early extinguishment of                      -0.06           -0.06  
  debt                                                                          
  Tax and noncontrolling interests                                              
  impact                                                 -4.40           -4.46  
  of above items                                                                
  Adjusted diluted earnings per                    $     22.05    $      23.01  
  share                                                                         
  Weighted average dilutive shares                      83,000          83,000  
  outstanding (in thousands)                                                    
  (1) The figures shown represent                                               
  the                                                                           
  Company's estimate for                                                        
  restructuring                                                                 
  charges plus the actual                                                       
  year-to-date                                                                  
  results for impairment and                                                    
  restructuring                                                                 
  charges, acquisition-related                                                  
  costs, and                                                                    
  litigation costs and settlements.                                             
  The                                                                           
  Company does not generally                                                    
  forecast                                                                      
  impairment charges,                                                           
  acquisition-related                                                           
  costs, and litigation costs and                                               
  settlements because it does not                                               
  believe                                                                       
  that it can forecast these items                                              
  with                                                                          
  sufficient accuracy since some of                                             
  these                                                                         
  items are indeterminable at the                                               
  time the                                                                      
  Company provides its financial                                                
  Outlook.                                                                      
  (2) The Company does not generally                                            
  forecast net gains (losses) on                                                
  sales,                                                                        
  consolidation and deconsolidation                                             
  of                                                                            
  facilities or gains (losses) from                                             
  early                                                                         
  extinguishment of debt because the                                            
  Company does not believe that it                                              
  can                                                                           
  forecast these items with                                                     
  sufficient                                                                    
  accuracy since it is                                                          
  indeterminable at                                                             
  the time the Company provides its                                             
  financial Outlook. The figures                                                
  shown                                                                         
  relate to transactions that have                                              
  already                                                                       
  occurred in 2026.                                                             
                                                                                
                                    Page 20                                     
                                                                                
                                       T                                        
                                                                                
                                                                                
                          ENET HEALTHCARE CORPORATION                           
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
 Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare 
           Corporation Common Shareholders to Outlook Adjusted EBITDA           
                                                                                
                                  (Unaudited)                                   
                                                                                
  (Dollars in millions)           FY 2026    Low               High             
 ────────────────────────────────────────────────────────────────────────────── 
  Net income available to                                                       
  Tenet Healthcare                           $     2,973       $      3,078     
  Corporation common                                                            
  shareholders                                                                  
  Less:                                                                         
  Net income available to                                                       
  noncontrolling                                    -910               -960     
  interests                                                                     
  Income tax expense                              -1,135             -1,170     
  Interest expense                                  -825               -815     
  Loss from early                                                               
  extinguishment of                                   -5                 -5     
  debt(2)                                                                       
  Other non-operating income,                        150                200     
  net                                                                           
  Net gains on sales,                                                           
  consolidation and                                   43                 43     
  deconsolidation of                                                            
  facilities(2)                                                                 
  Impairment and restructuring                                                  
  charges,                                                                      
  acquisition-related costs,                        -180               -150     
  and                                                                           
  litigation costs and                                                          
  settlements(1)                                                                
  Depreciation and                                  -865               -915     
  amortization                                                                  
  Revenue from contract                            1,650              1,650     
  termination                                                                   
  Adjusted EBITDA                            $     5,050       $      5,200     
  Net income available to                                                       
  Tenet Healthcare                           $     2,973       $      3,078     
  Corporation common                                                            
  shareholders                                                                  
  Net operating revenues                     $    22,050       $     22,450     
  Net income available to                                                       
  Tenet Healthcare                                                              
  Corporation common                                13.5  %            13.7  %  
  shareholders as a %                                                           
  of net operating revenues                                                     
  Adjusted EBITDA as a % of                                                     
  net operating                                     22.9  %            23.2  %  
  revenues (Adjusted EBITDA                                                     
  margin)                                                                       
  (1) The figures shown                                                         
  represent the                                                                 
  Company's estimate for                                                        
  restructuring                                                                 
  charges plus the actual                                                       
  year-to-date                                                                  
  results for impairment and                                                    
  restructuring                                                                 
  charges, acquisition-related                                                  
  costs, and                                                                    
  litigation costs and                                                          
  settlements. The                                                              
  Company does not generally                                                    
  forecast                                                                      
  impairment charges,                                                           
  acquisition-related                                                           
  costs, and litigation costs                                                   
  and                                                                           
  settlements because it does                                                   
  not believe                                                                   
  that it can forecast these                                                    
  items with                                                                    
  sufficient accuracy since                                                     
  some of these                                                                 
  items are indeterminable at                                                   
  the time the                                                                  
  Company provides its                                                          
  financial Outlook.                                                            
  (2) The Company does not                                                      
  generally                                                                     
  forecast net gains (losses)                                                   
  on sales,                                                                     
  consolidation and                                                             
  deconsolidation of                                                            
  facilities or gains (losses)                                                  
  from early                                                                    
  extinguishment of debt                                                        
  because the                                                                   
  Company does not believe                                                      
  that it can                                                                   
  forecast these items with                                                     
  sufficient                                                                    
  accuracy since it is                                                          
  indeterminable at                                                             
  the time the Company                                                          
  provides its                                                                  
  financial Outlook. The                                                        
  figures shown                                                                 
  relate to transactions that                                                   
  have already                                                                  
  occurred in 2026.                                                             
                                                                                
                                    Page 21                                     
                                                                                
                          TENET HEALTHCARE CORPORATION                          
                                                                                
                                                                                
                  Additional Supplemental Non-GAAP disclosures                  
                                                                                
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities 
         to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow          
                                                                                
                                  (Unaudited)                                   
                                                                             
                                              FY 2026                        
  (Dollars in millions)                       Low               High         
 ─────────────────────────────────────────────────────────────────────────── 
  Net cash provided by operating              $        3,885    $     4,315  
  activities                                                                 
  Purchases of property and equipment                   -700           -800  
  Free cash flow                              $        3,185    $     3,515  
  Net cash provided by operating              $        3,885    $     4,315  
  activities                                                                 
  Less:                                                                      
  Payments for restructuring charges,                                        
  acquisition-related costs and litigation              -180           -150  
  costs and settlements(1)                                                   
  Cash received for contract termination                 540            540  
  Adjusted net cash provided by operating              3,525          3,925  
  activities                                                                 
  Purchases of property and equipment                   -700           -800  
  Adjusted free cash flow(2)                  $        2,825    $     3,125  
  (1) The figures shown represent the                                        
  Company's estimate for restructuring                                       
  payments plus the actual year-to-date                                      
  payments for restructuring charges,                                        
  acquisition-related costs, and                                             
  litigation costs or settlements. The                                       
  Company does not generally forecast                                        
  payments for acquisition-related costs,                                    
  and litigation costs and settlements                                       
  because it does not believe that it can                                    
  forecast these items with sufficient                                       
  accuracy since some of these items are                                     
  indeterminable at the time the Company                                     
  provides its financial Outlook.                                            
  (2) The Company’s definition of Adjusted                                   
  Free Cash Flow does not include other                                      
  important uses of cash including (1)                                       
  cash used to purchase businesses or                                        
  joint venture interests, or (2) any                                        
  items that are classified as Cash Flows                                    
  From Financing Activities on the                                           
  Company’s Consolidated Statement of Cash                                   
  Flows, including items such as (i) cash                                    
  used to repay borrowings, and (ii)                                         
  distributions paid to noncontrolling                                       
  interests.                                                                 
                                                                             
                                    Page 22                                     

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/THC/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.